Stephen Plymate
Overview
Explore the profile of Stephen Plymate including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van-Duyne G, Blair I, Sprenger C, Moiseenkova-Bell V, Plymate S, Penning T
Vitam Horm
. 2023 Sep;
123:439-481.
PMID: 37717994
The Androgen Receptor (AR) is a ligand (androgen) activated transcription factor and a member of the nuclear receptor (NR) superfamily. It is required for male sex hormone function. AR-FL (full-length)...
2.
Penning T, Asangani I, Sprenger C, Plymate S
Cancer Drug Resist
. 2022 May;
3(4):912-929.
PMID: 35582223
Castration-resistant prostate cancer is the lethal form of prostate cancer and most commonly remains dependent on androgen receptor (AR) signaling. Current therapies use AR signaling inhibitors (ARSI) exemplified by abiraterone...
3.
Asangani I, Blair I, Van Duyne G, Hilser V, Moiseenkova-Bell V, Plymate S, et al.
J Biol Chem
. 2021 Jan;
296:100240.
PMID: 33384381
Castration resistant prostate cancer (CRPC) continues to be androgen receptor (AR) driven. Inhibition of AR signaling in CRPC could be advanced using state-of-the-art biophysical and biochemical techniques. Structural characterization of...
4.
5.
Luo J, Attard G, Balk S, Bevan C, Burnstein K, Cato L, et al.
Eur Urol
. 2017 Dec;
73(5):715-723.
PMID: 29258679
Context: Although a number of studies have demonstrated the importance of constitutively active androgen receptor variants (AR-Vs) in prostate cancer, questions still remain about the precise role of AR-Vs in...
6.
Mohammad O, Nyquist M, Schweizer M, Balk S, Corey E, Plymate S, et al.
Cancers (Basel)
. 2017 Dec;
9(12).
PMID: 29210989
Since Huggins defined the androgen-sensitive nature of prostate cancer (PCa), suppression of systemic testosterone (T) has remained the most effective initial therapy for advanced disease although progression inevitably occurs. From...
7.
Montgomery B, Tretiakova M, Joshua A, Gleave M, Fleshner N, Bubley G, et al.
Clin Cancer Res
. 2017 Feb;
23(9):2169-2176.
PMID: 28151719
Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or eliminate micrometastases. We evaluated neoadjuvant therapy prior to prostatectomy with...
8.
Yang Y, Banuelos C, Mawji N, Wang J, Kato M, Haile S, et al.
Clin Cancer Res
. 2016 May;
22(17):4466-77.
PMID: 27140928
Purpose: Persistent androgen receptor (AR) transcriptional activity is clinically evident in castration-resistant prostate cancer (CRPC). Therefore, AR remains as a viable therapeutic target for CRPC. All current hormonal therapies target...
9.
Zhang A, Zhang J, Plymate S, Mostaghel E
Horm Cancer
. 2016 Jan;
7(2):104-13.
PMID: 26797685
Androgens play an important role in prostate cancer (PCa) development and progression. Accordingly, androgen deprivation therapy remains the front-line treatment for locally recurrent or advanced PCa, but patients eventually relapse...
10.
Mostaghel E, Zhang A, Plymate S
Eur Urol
. 2015 Aug;
69(4):610-612.
PMID: 26318705
No abstract available.